BR112016001316B1 - Método de formação de imagem útil no diagnóstico dedoença neurológica, meio de armazenamento de memória, e, uso de um meio de armazenamento de memória - Google Patents
Método de formação de imagem útil no diagnóstico dedoença neurológica, meio de armazenamento de memória, e, uso de um meio de armazenamento de memória Download PDFInfo
- Publication number
- BR112016001316B1 BR112016001316B1 BR112016001316-6A BR112016001316A BR112016001316B1 BR 112016001316 B1 BR112016001316 B1 BR 112016001316B1 BR 112016001316 A BR112016001316 A BR 112016001316A BR 112016001316 B1 BR112016001316 B1 BR 112016001316B1
- Authority
- BR
- Brazil
- Prior art keywords
- normal
- imaging
- radiopharmaceutical
- individual
- memory storage
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 76
- 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 22
- 208000025966 Neurological disease Diseases 0.000 title claims abstract description 22
- 238000003745 diagnosis Methods 0.000 title claims abstract description 20
- 230000005055 memory storage Effects 0.000 title claims 6
- 239000012217 radiopharmaceutical Substances 0.000 claims abstract description 53
- 229940121896 radiopharmaceutical Drugs 0.000 claims abstract description 53
- 230000002799 radiopharmaceutical effect Effects 0.000 claims abstract description 53
- 238000010521 absorption reaction Methods 0.000 claims abstract description 45
- 210000001577 neostriatum Anatomy 0.000 claims abstract description 29
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 claims abstract description 25
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims abstract description 25
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 18
- 210000004556 brain Anatomy 0.000 claims abstract description 18
- 210000002637 putamen Anatomy 0.000 claims description 23
- 208000018737 Parkinson disease Diseases 0.000 claims description 21
- HXWLAJVUJSVENX-HFIFKADTSA-N ioflupane I(123) Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3CCCF)[C@H]2C(=O)OC)=CC=C([123I])C=C1 HXWLAJVUJSVENX-HFIFKADTSA-N 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 13
- 206010034010 Parkinsonism Diseases 0.000 claims description 11
- 201000002832 Lewy body dementia Diseases 0.000 claims description 8
- GTQLIPQFXVKRKJ-HYRAKNMCSA-N methyl (1s,3s,4s,5r)-3-(4-fluorophenyl)-8-[(e)-3-iodanylprop-2-enyl]-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C\C=C\[123I])[C@H]2C(=O)OC)=CC=C(F)C=C1 GTQLIPQFXVKRKJ-HYRAKNMCSA-N 0.000 claims description 5
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 4
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims description 4
- 229930004006 tropane Natural products 0.000 claims description 4
- HXWLAJVUJSVENX-LNYNZGDVSA-N methyl (1R,2S,3S,5S)-8-(3-(18F)fluoranylpropyl)-3-(4-iodophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3CCC[18F])[C@H]2C(=O)OC)=CC=C(I)C=C1 HXWLAJVUJSVENX-LNYNZGDVSA-N 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 abstract description 53
- 238000002560 therapeutic procedure Methods 0.000 abstract description 15
- 238000004364 calculation method Methods 0.000 abstract description 12
- 238000002405 diagnostic procedure Methods 0.000 abstract description 11
- 238000012544 monitoring process Methods 0.000 abstract description 10
- 230000007717 exclusion Effects 0.000 abstract description 2
- 238000010187 selection method Methods 0.000 abstract description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 49
- 230000009102 absorption Effects 0.000 description 43
- 229960003638 dopamine Drugs 0.000 description 23
- 230000002159 abnormal effect Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000002600 positron emission tomography Methods 0.000 description 11
- 229960004898 ioflupane i-123 Drugs 0.000 description 10
- 230000003518 presynaptic effect Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 208000027089 Parkinsonian disease Diseases 0.000 description 8
- 238000012937 correction Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 201000006517 essential tremor Diseases 0.000 description 8
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 208000001089 Multiple system atrophy Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012216 imaging agent Substances 0.000 description 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229960004502 levodopa Drugs 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 210000001638 cerebellum Anatomy 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002610 neuroimaging Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012879 PET imaging Methods 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- WAOQONBSWFLFPE-TXWZUYSVSA-N 3,5-dichloro-n-[[(2s)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1O[11CH3] WAOQONBSWFLFPE-TXWZUYSVSA-N 0.000 description 2
- -1 3-fluoropropoxy Chemical group 0.000 description 2
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 2
- 101150049660 DRD2 gene Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 2
- 206010068100 Vascular parkinsonism Diseases 0.000 description 2
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 description 2
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000000648 anti-parkinson Effects 0.000 description 2
- 239000000939 antiparkinson agent Substances 0.000 description 2
- 238000003705 background correction Methods 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052755 nonmetal Inorganic materials 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- VGZDEVKDDGMADS-AGUYFDCRSA-N (1s,5r)-8-methyl-3-phenyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@]1(CC[C@@](C2)(N1C)[H])[H])C2C1=CC=CC=C1 VGZDEVKDDGMADS-AGUYFDCRSA-N 0.000 description 1
- WEQLWGNDNRARGE-DJIMGWMZSA-N (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol Chemical class C1CN2C[C@@H](CC(C)C)[C@H](O)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 WEQLWGNDNRARGE-DJIMGWMZSA-N 0.000 description 1
- PAXWQORCRCBOCU-RPDRGXCHSA-N 6-((18)F)fluoro-L-dopa Chemical compound OC(=O)[C@@H](N)CC1=CC(O)=C(O)C=C1[18F] PAXWQORCRCBOCU-RPDRGXCHSA-N 0.000 description 1
- WEQLWGNDNRARGE-KTXUZGJCSA-N 9,10-di(methoxy)-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-ol Chemical compound C12CC(O)C(CC(C)C)CN2CCC2=C1C=C(OC)C(O[11CH3])=C2 WEQLWGNDNRARGE-KTXUZGJCSA-N 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 241000405147 Hermes Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241001664469 Tibicina haematodes Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010249 dopaminergic function Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000002425 internal capsule Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000011410 subtraction method Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Neurosurgery (AREA)
- Dentistry (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nuclear Medicine (AREA)
- Pulmonology (AREA)
- Theoretical Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Primary Health Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1313291.5A GB201313291D0 (en) | 2013-07-25 | 2013-07-25 | Imaging neurological disease |
| GB1313291.5 | 2013-07-25 | ||
| PCT/EP2014/066042 WO2015011267A1 (en) | 2013-07-25 | 2014-07-25 | Imaging neurological disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016001316B1 true BR112016001316B1 (pt) | 2021-04-06 |
Family
ID=49166921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016001316-6A BR112016001316B1 (pt) | 2013-07-25 | 2014-07-25 | Método de formação de imagem útil no diagnóstico dedoença neurológica, meio de armazenamento de memória, e, uso de um meio de armazenamento de memória |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11051777B2 (enExample) |
| EP (1) | EP3024501B1 (enExample) |
| JP (1) | JP6590801B2 (enExample) |
| KR (1) | KR102340504B1 (enExample) |
| CN (1) | CN105392500B (enExample) |
| AU (2) | AU2014294983B2 (enExample) |
| BR (1) | BR112016001316B1 (enExample) |
| CA (1) | CA2916125A1 (enExample) |
| DK (1) | DK3024501T3 (enExample) |
| ES (1) | ES2722973T3 (enExample) |
| GB (1) | GB201313291D0 (enExample) |
| IL (1) | IL243383B (enExample) |
| MX (1) | MX2016001012A (enExample) |
| RU (1) | RU2015155792A (enExample) |
| SG (1) | SG11201600571RA (enExample) |
| WO (1) | WO2015011267A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104720840A (zh) * | 2015-02-11 | 2015-06-24 | 清华大学深圳研究生院 | 基于多巴胺转运体显像特异性摄取比的半自动量化方法 |
| TWI587841B (zh) * | 2015-03-06 | 2017-06-21 | 國立陽明大學 | 定量分析核子醫學腦部影像的系統及方法 |
| US20180000440A1 (en) * | 2015-03-24 | 2018-01-04 | Nihon Medi-Physics Co., Ltd. | Image processing apparatus, image processing method, and program |
| KR101720288B1 (ko) | 2016-05-11 | 2017-03-28 | (주)바이오액츠 | 뇌 영상용 염료 및 이의 제조방법 |
| JP6549521B2 (ja) * | 2016-05-25 | 2019-07-24 | 富士フイルム富山化学株式会社 | 疾患鑑別支援装置及びコンピュータプログラム |
| TWI607739B (zh) * | 2016-05-27 | 2017-12-11 | 許百靈 | Ｓｐｅｃｔ多巴胺顯像定量分析技術與在腦多巴胺評估的用途 |
| GB201621698D0 (en) * | 2016-12-20 | 2017-02-01 | Ge Healthcare Ltd (Ip) And Stichting Vumc And Acad Medical Center | Differential Diagnosis |
| JP6995642B2 (ja) * | 2018-01-19 | 2022-01-14 | 日本メジフィジックス株式会社 | 画像処理装置、画像処理方法およびプログラム |
| TWI686178B (zh) * | 2019-10-09 | 2020-03-01 | 中原大學 | 自動化定位核子醫學腦部影像紋狀體與計算紋狀體專一性攝取率的方法與系統 |
| US20230001026A1 (en) * | 2019-11-21 | 2023-01-05 | Likeminds, Inc. | Pharmaceutical packaging units and methods for concomitant administration of radiotracers |
| AR125188A1 (es) | 2021-03-22 | 2023-06-21 | Neurocrine Biosciences Inc | Inhibidores del vmat2 y métodos de uso |
| CN119599879B (zh) * | 2024-11-06 | 2025-10-24 | 复旦大学附属华山医院 | 一种基于深度学习的pet图像跨膜态合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009040727A2 (en) * | 2007-09-26 | 2009-04-02 | Philips Intellectual Property & Standards Gmbh | Method of differentially diagnosing different types of dementia |
| US8084018B2 (en) * | 2007-10-31 | 2011-12-27 | Alseres Pharmaceuticals, Inc. | Methods for imaging dopamine transporter level |
| US20100312105A1 (en) * | 2007-10-31 | 2010-12-09 | Alseres Pharmaceuticals, Inc. | Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level |
-
2013
- 2013-07-25 GB GBGB1313291.5A patent/GB201313291D0/en not_active Ceased
-
2014
- 2014-07-25 BR BR112016001316-6A patent/BR112016001316B1/pt active IP Right Grant
- 2014-07-25 CN CN201480041743.1A patent/CN105392500B/zh active Active
- 2014-07-25 WO PCT/EP2014/066042 patent/WO2015011267A1/en not_active Ceased
- 2014-07-25 DK DK14742544.1T patent/DK3024501T3/da active
- 2014-07-25 KR KR1020167001611A patent/KR102340504B1/ko active Active
- 2014-07-25 JP JP2016528546A patent/JP6590801B2/ja active Active
- 2014-07-25 RU RU2015155792A patent/RU2015155792A/ru unknown
- 2014-07-25 US US14/907,428 patent/US11051777B2/en active Active
- 2014-07-25 MX MX2016001012A patent/MX2016001012A/es unknown
- 2014-07-25 SG SG11201600571RA patent/SG11201600571RA/en unknown
- 2014-07-25 EP EP14742544.1A patent/EP3024501B1/en active Active
- 2014-07-25 CA CA2916125A patent/CA2916125A1/en not_active Abandoned
- 2014-07-25 AU AU2014294983A patent/AU2014294983B2/en active Active
- 2014-07-25 ES ES14742544T patent/ES2722973T3/es active Active
-
2015
- 2015-12-28 IL IL243383A patent/IL243383B/en active IP Right Grant
-
2019
- 2019-10-23 AU AU2019253837A patent/AU2019253837B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105392500B (zh) | 2023-08-18 |
| WO2015011267A1 (en) | 2015-01-29 |
| IL243383B (en) | 2018-07-31 |
| RU2015155792A3 (enExample) | 2018-05-23 |
| CA2916125A1 (en) | 2015-01-29 |
| US11051777B2 (en) | 2021-07-06 |
| GB201313291D0 (en) | 2013-09-11 |
| AU2014294983A1 (en) | 2016-01-21 |
| RU2015155792A (ru) | 2017-08-30 |
| JP6590801B2 (ja) | 2019-10-16 |
| HK1222118A1 (zh) | 2017-06-23 |
| ES2722973T3 (es) | 2019-08-20 |
| KR102340504B1 (ko) | 2021-12-20 |
| EP3024501A1 (en) | 2016-06-01 |
| KR20160037168A (ko) | 2016-04-05 |
| EP3024501B1 (en) | 2019-03-27 |
| DK3024501T3 (da) | 2019-05-06 |
| US20160183897A1 (en) | 2016-06-30 |
| SG11201600571RA (en) | 2016-02-26 |
| JP2016531903A (ja) | 2016-10-13 |
| AU2014294983B2 (en) | 2019-10-24 |
| AU2019253837A1 (en) | 2019-11-14 |
| AU2019253837B2 (en) | 2021-11-25 |
| CN105392500A (zh) | 2016-03-09 |
| MX2016001012A (es) | 2016-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019253837B2 (en) | Imaging neurological disease | |
| Politis et al. | Positron emission tomography imaging in neurological disorders | |
| Zhu et al. | PET/SPECT imaging agents for neurodegenerative diseases | |
| Hickey et al. | Diagnostic imaging of Alzheimer's disease with copper and technetium complexes | |
| Masterman et al. | Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer's disease from other dementias | |
| JP5603855B2 (ja) | 神経変成疾患の放射性薬剤による画像化 | |
| Maddahi | Properties of an ideal PET perfusion tracer: new PET tracer cases and data | |
| Hsiao et al. | Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson’s disease patients | |
| JP2010540512A (ja) | 異なるタイプの認知症を特異的に診断する方法 | |
| Booij et al. | Imaging of striatal dopamine transporters in rat brain with single pinhole SPECT and co-aligned MRI is highly reproducible | |
| Kurtys et al. | Evaluating [11C] PBR28 PET for monitoring gut and brain inflammation in a rat model of chemically induced colitis | |
| Pain et al. | Human biodistribution and internal dosimetry of 4-[18 F] fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart | |
| Edison et al. | Strategies for the generation of parametric images of [11C] PIB with plasma input functions considering discriminations and reproducibility | |
| Huang et al. | Chronic manganism: a long-term follow-up study with a new dopamine terminal biomarker of 18F-FP-(+)-DTBZ (18F-AV-133) brain PET scan | |
| Kreimerman et al. | Biological Assessment of a 18F-Labeled Sulforhodamine 101 in a Mouse Model of Alzheimer’s Disease as a Potential Astrocytosis Marker | |
| WO2019023815A1 (es) | Nuevos compuestos derivados de piridinmetilsulfinilbenzoxazoles y piridinmetilsulfinibenzotiazoles, marcados radiactivamente o con fluorescencia y sus composiciones, como biomarcadores especificos para el diagnostico de enfermedades neurodegenerativas y patologías involucradas con la proteína tau | |
| Hägerström et al. | A new automated method for analysis of rCBF‐SPECT images based on the active‐shape algorithm: normal values | |
| He | Detecting and quantifying c-fos in vivo by PET imaging of DREADD-expressing neurons in mice brains after sleep deprivation | |
| HK1222118B (zh) | 成像神经学疾病 | |
| Holman et al. | SPECT Imaging in Alzheimer's Disease | |
| Scherfler et al. | Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [123I] β-CIT SPECT analysis | |
| RU2692451C2 (ru) | Способ радионуклидной диагностики опухолей головного мозга | |
| de Oliveira Mota et al. | Efficacy and safety of 99mTc-Trodat-1 in the early and differential diagnosis of Parkinson’s disease | |
| RU2629044C1 (ru) | Способ количественного определения накопления радиофармпрепарата при радионуклидном исследовании перфузии легких | |
| Dobbeleir et al. | 4. Perfusion of the brain. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/07/2014, OBSERVADAS AS CONDICOES LEGAIS. |